TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0

CUSIP: 89422GAA5

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class
Debt / NOTE 2.250% 3/0
Market price (% of par)
95.39%
Total 13F principal
$279,664,978
Principal change
+$2,653,685
Total reported market value
$303,344,890
Number of holders
26
Value change
+$1,782,692
Number of buys
13
Number of sells
14

Quarterly Holders Quick Answers

What is CUSIP 89422GAA5?
CUSIP 89422GAA5 identifies 89422GAA5 - TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q2 2025

As of 30 Jun 2025, TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 was held by 26 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $279,664,978 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, D. E. Shaw & Co., Inc., Graham Capital Management, L.P., ADVENT CAPITAL MANAGEMENT /DE/, AGF MANAGEMENT LTD, JANUS HENDERSON GROUP PLC, LORD, ABBETT & CO. LLC, Jump Financial, LLC, OAKTREE CAPITAL MANAGEMENT LP, and Affinity Asset Advisors, LLC. This page lists 26 institutional bondholders reporting positions for the Q2 2025 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.